Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis.
Expert review of anticancer therapy（2023）
摘要
This meta-analysis indicates that patients with CDK12 mutation have poor prognosis in PCa. CDK12 may be used as a biomarker for molecular subtype and a potential therapeutic target of PCa.
更多查看译文
关键词
CDK12,Cyclin-dependent kinase 12,Meta-analysis,genomics,prognosis,prostate cancer
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要